{"filing":{"accession_number":"0001213900-26-075514","cik":"0001721484","ticker":"LGVN","company_name":"Longeveron Inc.","form":"8-K","filing_date":"2026-07-06","report_date":null,"primary_document":"ea0297153-8k_longeveron.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1721484/000121390026075514/ea0297153-8k_longeveron.htm"},"events":[{"id":17076,"run_id":15287,"accession_number":"0001213900-26-075514","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"summary":"Marie Washburn appointed as Senior Vice President and Chief Financial Officer effective July 13, 2026, with compensation terms including $340,000 base salary, 45% performance bonus target, and 130,000 RSUs. Dr. Arjun Desai also appointed to the Board as a Class III director on July 2, 2026.","company_name":"Longeveron Inc.","ticker":"LGVN","filing_date":"2026-07-06","form":"8-K","submitted_at":null,"items":[{"id":15390,"accession_number":"0001213900-26-075514","item_number":"5.02","item_title":"Departure of","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The filing discloses two executive appointments: (1) Marie Washburn appointed as Senior Vice President and Chief Financial Officer effective July 13, 2026, with detailed compensation terms including $340,000 base salary, 45% performance bonus target, and 130,000 RSUs; and (2) Dr. Arjun Desai appointed to the Board as a Class III director on July 2, 2026. While the section also mentions Lisa Locklear's departure as CFO, the principal disclosed action centers on Washburn's appointment to fill the CFO role with specific compensation arrangements, making this an exec_appointment event. The appointment of a new CFO at a clinical-stage biotech company is material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T12:50:29.141773+00:00","company_name":"","ticker":null,"filing_date":""},{"id":15391,"accession_number":"0001213900-26-075514","item_number":"5.03","item_title":"Amendments to Articles of Incorporation or Bylaws; Change","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The primary disclosed event is the appointment of Marie Washburn as Senior Vice President and Chief Financial Officer of Longeveron, effective July 13, 2026. While Item 5.03 addresses the Charter Amendment increasing authorized Class A common stock, the substantive material event disclosed in the 8-K is the executive appointment documented in the press release (EX-99.1). Washburn's appointment to the principal financial officer and principal accounting officer roles, succeeding Lisa Locklear, constitutes a material executive appointment at a clinical-stage biotech company with significant ongoing clinical trials.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T12:50:29.141773+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":17077,"run_id":15287,"accession_number":"0001213900-26-075514","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Longeveron's Annual Meeting held July 1, 2026 approved six proposals: election of three Class II directors (Stephen Willard, Leah Rush Cann, Deborah Ascheim), charter amendments to increase authorized Class A shares and authorize a reverse stock split (1:2 to 1:20 ratio), amendment to the 2021 Incentive Award Plan to increase authorized shares by 5,000,000, ratification of CBIZ CPAs P.C. as independent auditor, and approval of an adjournment proposal.","company_name":"Longeveron Inc.","ticker":"LGVN","filing_date":"2026-07-06","form":"8-K","submitted_at":null,"items":[{"id":15392,"accession_number":"0001213900-26-075514","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Item 5.07 discloses the results of Longeveron's Annual Meeting held July 1, 2026, with detailed voting tallies on six proposals: election of three Class II directors (Stephen Willard, Leah Rush Cann, Deborah Ascheim), approval of charter amendments to increase authorized Class A shares and authorize a reverse stock split (1:2 to 1:20 ratio), approval of an amendment to the 2021 Incentive Award Plan to increase authorized shares by 5,000,000, ratification of CBIZ CPAs P.C. as independent auditor, and approval of an adjournment proposal. The voting results are material to investors as they reflect shareholder approval of significant corporate actions including capital structure changes and equity plan expansion.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T12:50:29.141773+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":15390,"accession_number":"0001213900-26-075514","item_number":"5.02","item_title":"Departure of","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The filing discloses two executive appointments: (1) Marie Washburn appointed as Senior Vice President and Chief Financial Officer effective July 13, 2026, with detailed compensation terms including $340,000 base salary, 45% performance bonus target, and 130,000 RSUs; and (2) Dr. Arjun Desai appointed to the Board as a Class III director on July 2, 2026. While the section also mentions Lisa Locklear's departure as CFO, the principal disclosed action centers on Washburn's appointment to fill the CFO role with specific compensation arrangements, making this an exec_appointment event. The appointment of a new CFO at a clinical-stage biotech company is material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T12:50:29.141773+00:00","company_name":"Longeveron Inc.","ticker":"LGVN","filing_date":"2026-07-06"},{"id":15391,"accession_number":"0001213900-26-075514","item_number":"5.03","item_title":"Amendments to Articles of Incorporation or Bylaws; Change","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The primary disclosed event is the appointment of Marie Washburn as Senior Vice President and Chief Financial Officer of Longeveron, effective July 13, 2026. While Item 5.03 addresses the Charter Amendment increasing authorized Class A common stock, the substantive material event disclosed in the 8-K is the executive appointment documented in the press release (EX-99.1). Washburn's appointment to the principal financial officer and principal accounting officer roles, succeeding Lisa Locklear, constitutes a material executive appointment at a clinical-stage biotech company with significant ongoing clinical trials.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T12:50:29.141773+00:00","company_name":"Longeveron Inc.","ticker":"LGVN","filing_date":"2026-07-06"},{"id":15392,"accession_number":"0001213900-26-075514","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Item 5.07 discloses the results of Longeveron's Annual Meeting held July 1, 2026, with detailed voting tallies on six proposals: election of three Class II directors (Stephen Willard, Leah Rush Cann, Deborah Ascheim), approval of charter amendments to increase authorized Class A shares and authorize a reverse stock split (1:2 to 1:20 ratio), approval of an amendment to the 2021 Incentive Award Plan to increase authorized shares by 5,000,000, ratification of CBIZ CPAs P.C. as independent auditor, and approval of an adjournment proposal. The voting results are material to investors as they reflect shareholder approval of significant corporate actions including capital structure changes and equity plan expansion.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T12:50:29.141773+00:00","company_name":"Longeveron Inc.","ticker":"LGVN","filing_date":"2026-07-06"}]}